Summit notes Akeso reported OS benefit in HARMONi-2
Summit Therapeutics said partner Akeso reported ivonescimab achieved a statistically significant overall survival benefit versus pembrolizumab in the Phase III HARMONi-2 study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.